Research programme: microRNA therapeutics - Regulus Therapeutics/Sanofi

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics/Sanofi

Alternative Names: anti-miR-21; microRNA-21 therapeutics; microRNA-221/microRNA-222 therapeutics; miR-221/222 therapeutics; miRNA-21 therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Regulus Therapeutics; sanofi-aventis
  • Developer Regulus Therapeutics; Sanofi
  • Class MicroRNAs; Oligonucleotides
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrosis; Hepatocellular carcinoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatocellular carcinoma in USA
  • 13 Feb 2014 Regulus Therapeutics and Sanofi renew agreement to co-develop microRNA therapeutics for Fibrosis and Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top